Infecciones severas en pacientes con artritis reumatoide tratados con fármacos antagonistas del factor de necrosis tumoral alfa

Autores/as

  • Marvin Sánchez Benavides Caja Costarricense del Seguro Social, Hospital Dr. Rafael A. Calderón Guardia
  • Adolfo Pacheco Salazar Caja Costarricense del Seguro Social, Hospital Dr. Rafael A. Calderón Guardia
  • Pablo Monge Zeledón Caja Costarricense del Seguro Social, Hospital México

DOI:

https://doi.org/10.51481/amc.v59i1.948

Palabras clave:

artritis reumatoide, terapia antiTNF, infecciones severas, epidemiología, drogas antirreumáticas modificadoras de enfermedad, prevalencia

Resumen

El uso de fármacos antagonistas del factor de necrosis tumoral alfa se asocia a infecciones severas en artritis reumatoide, con una alta morbi-mortalidad en la práctica clínica. No existe casuística publicada respecto al tema en nuestro país. Se pretende aportar información relacionada con la epidemiología local de las infecciones severas e identificar factores de riesgo asociados.

Citas

Seymour HE, Worsley A, Smith JM, Thomas SHL. Anti TNFagents for rheumatoid arthritis. Br J Clin Pharmacol 2001; 51:201-208

Delgado-Vega AM, Martin J, Granados J, Anaya JM. Epidemiología genética de la artritis reumatoide ¿Qué esperar para América Latina? Biomédica 2006; 26:562-84

Carmona L, Villaverde V, Hernández-García C, Ballina J, Gabriel R, Lafon A, et al. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology 2002; 41:88–95

Goh L, Jewell T, Laversuch T, Samantha A. A systematic review of the influence of anti-TNFon infection rates in patients with rheumatoid arthritis. Rev Bras Reumatol 2013; 53:501-515.

Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DPM. Rates of serious infections, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumour necrosis factor therapy. Arthritis Rheum 2006; 54:2368-2376

Haroon N, Inman R. Infectious complications of biological therapy. Curr Opin Rheumatol 2009; 21:397-403

Listing J, Strangfeld A, Kary S, Rau R, Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52:3403-3412

Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumour necrosis factor α therapy. Arthritis Rheum 2013; 48:3013-3022

Zuo JX, Braun J, Sieper J. Immunological basis for the use of TNF -blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin Exp Rheumatol 2002; 20:S34-S37

Sacca R, Cuff C, Lesslauer W, Ruddle NH. Differential activities of secreted lymphotoxin-alpha3 and membrane lymphotoxin-alpha1beta2 in lymphotoxininduced inflammation: critical role of TNF receptor 1 signaling, J Immunol 1998; 160:485–491

Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families, N Engl J Med 1996; 334:1717–1725

Feldman M, Elliot MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-a therapy of rheumatoid arthritis. Adv Immunol 1997; 64:283–350

Martin-Mola E, Balsa A. Infectious complications of biologic agents. Rheum Dis Clin N Am 2009; 35:183-199

Kavanaugh A, Cohen S, Cush JJ. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis. J Rheumatol 2004; 31:1881-1884

van Dartel SA, Fransen J, Kievit W, Dutmer EA, Brus HLM, Houtman NM et al. Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology 2012; 52:1052-1057

Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70:616-623

Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, et al. Nonviral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the Safety Assesment of Biologic Therapy (SABER) Study. Ann Rheum Dis 2013; 0:1-7

Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius L, et al. Time-dependent increase in risk of hospitalisation with infection among swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66:1339–1344

Wallis RS. Biologics and infections: lessons from tumor necrosis factor blocking agents. Infect Dis Clin N Am 2011; 25:895–910

St. Claire EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:1451-1459

Lipsky PE, van der Heijde D, St. Clair EW, Furst DE, Breedveld FC, Kalden, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343:1594-1602

Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ et al. Etanercept therapy in rheumatoid arthritis. Ann Intern Med. 1999; 130:478-486

den Broeder AA, Joosten LAB, Saxne T, Heinegard D, Fenner H, Miltenburg AMM et al: Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation, Ann Rheum Dis 2002; 61:311–318

Lorenz HM, Antoni C, Valerius T, Repp R, Grunke M, Schwerdtner N, et al: In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis: short term cellular and molecular effects, J Immunol 156:1646–1653, 1996

Charles P, Elliot MJ, Davis D, Potter A, Kalden JR, Antoni C et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Inmunnol 1999; 163:1521-1528

Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L et al. Anti tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 2002; 41:484-489

Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard M, et al. Infections during tumour necrosis factor α blocker therapy for rheumatic disease in daily practice: a systematic retrospective study of 709 patients. Rheumatology 2007; 46:327-334

Bernatsky S, Habel Y, Rahme E. Observational studies of infections in rheumatoid arthritis: a metaanalisys of tumour necrosis factor antagonist. J Rheumatol 2010; 37:928-931

Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti- TNF therapy: Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70:1810-1814

Patkar NM, Teng GG, Curtis JR, Saag KG. Association of infections and tuberculosis with antitumour necrosis factor alpha therapy. Curr Opin Rheumatol 2008; 20:320-326

Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. AntiTNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275-2285

Stenger S. Inmunological control of tuberculosis: rol of tumour necrosis factor and more. Ann Rheum Dis 2005; 64:iv24-iv28

Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, et al. Mycobacterial disease and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013; 72:37-42

Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of antiTNF therapy and increased risk of infections. Drug, Healthcare and Patient Safety 2013; 5:79-99

Galloway JB, Mercer LK, Moseley A, Dixon WG, Uistianoswski AP, Helbert M, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013; 72:229-234

Inanc N, Direskeneli H. Serious infections under treatment with TNFα antagonists compared to traditional DMARDs in patients with rheumatoid arthritis. Rheumatol Int 2006; 27:67–71

Doran MF, Crowson CS, Pond GR, O´Fallon WM, Gabriel SE. Frequency of infection in patients with heumatoid arthritis compared with controls. Arthritis

Rheum 2002; 46:2287-2293

Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: update results from the British Society for Rheumatology Biologics Register with special emphasis on risk in the erdely. Rheumatology 2011; 50:124-131

Greenberg J, Reed G, Decktor D. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134–1142

Kameda H, Ueki Y, Saito K. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol, 2010;20:531–538

Takeuchi T, Tanaka Y, Kaneko Y. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol (2012) 22:327–338

Burmester G, Mariette X, Montecucco C. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007;66:732–739

Singh J, Furst D, Bharat A. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care & Research Vol. 64, No. 5, May 2012, pp 625–639

Calabrese LH, Zein N, Vassilopoulosen D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004;63(Suppl II):ii18–ii24

Gonzales-Malaver F, Guzman-Vergara CM, Bello-Gualtero JM, Varela J, MesaBetancourt AM, Londoño J, et al. Latent tuberculosis infection and viral hepatitis in a Colombian cohort of patients with biological therapy. Ann Rheum Dis 2013 71:278

Nacci F, Matucci-Cerinic M. Tuberculosis and other infections in the antitumour necrosis factor-alpha (anti-TNF-α) era. Best Pract Res Clin Rheumatol.

Jun;25:375-88

Descargas

Publicado

2017-02-01 — Actualizado el 2017-02-02

Versiones

Cómo citar

Benavides, M. S., Salazar, A. P., & Zeledón, P. M. (2017). Infecciones severas en pacientes con artritis reumatoide tratados con fármacos antagonistas del factor de necrosis tumoral alfa. Acta Médica Costarricense, 59(1), 15–21. https://doi.org/10.51481/amc.v59i1.948 (Original work published 1 de febrero de 2017)

Artículos más leídos del mismo autor/a